- 1 Monitoring the battleground: Antimicrobial resistance, antibiofilm patterns, and virulence
- 2 factors of wound bacterial isolates from patients in hospital system.
- 3
- Silas O. Awuor <sup>a.\*</sup>, Richard Mariita <sup>b.</sup>, Eric O. Omwenga <sup>c.</sup>, Jonathan Musila <sup>d.</sup>,
   *Stanslaus Musvoki* <sup>e.</sup>
- 5 Stanstaus Musyoni
- <sup>a.</sup> Microbiology Department, Jaramogi Oginga Odinga Teaching and Referral Hospital, P.O
  Box 849, Kisumu, Kenya.
- 8 <sup>b.</sup> Microbial BioSolutions, Troy, New York, 12180 USA
- 9 <sup>C.</sup> Department of Medical Microbiology & Parasitology, School of Health Sciences, Kisii
- 10 University P.O. Box 408 40200 Kisii
- 11 *d. Fayetteville State University, NC 28301 USA*
- <sup>e.</sup> Department of Medical Laboratory Sciences, School of Health Sciences, South Eastern Kenya
   University; P.O. Box 170-90200, Kitui, Kenya
- 14
- 15 \*Corresponding author: awuorhsd@otti.ac.ke
- 16
- 17 Email address
- 18 1. RM- <u>richard.mariita@microbialbiosolutions.com</u>
- 19 2. EO- *omorieric@kisiiuniversity.ac.ke*
- 20 3. JM-<u>jmusila@broncos.uncfsu.edu</u>
- 21 4. SM- <u>stanslausmusyoki01@gmail.com</u>

22 23

### 25 ABSTRACT

Extensive use of antibiotics in the treatment of bacterial infections has led to a challenge of antibiotic 26 27 resistance, contributing to morbidity and mortality. Herein, evaluation of bacterial isolates from patients 28 with wound discharge was performed and drug susceptibility patterns examined, with a goal of deciphering 29 antibacterial resistance. A cross-sectional study was conducted between March to June 2022, in which 30 samples were collected from patients with chronic wounds and were inoculated into appropriate media for 31 identification and characterization. The bacterial pathogens were identified using standard microbiological methods. Shockingly, the majority of wound isolates showed positive growth in microbial analysis 32 33 with high prevalence in male candidates. Further, Staphylococcus aureus 28 (20.7%) was identified as the most predominant pathogen followed by Klebsiella spp. 20 (14.8%), P. 34 aeruginosa spp. 10 (14.8%) and lastly E. coli 6 (4.4%) bacteria in the wound isolates while 35 cotrimoxazole 13 (48.1%) followed by clindamycin 7 (25.9%) and erythromycin 7 (25.9%) were 36 the most antibacterial resistant drugs to both Gram positive and Gram-negative bacteria. Out of 37 the four isolates, 3 (75%) isolates were able to produce the haemolysin and protease and 2 (50%) 38 isolates were able to produce the lipase and phospholipase. The findings herein form a clinical 39 basis for identification of antimicrobial resistance in chronic wounds that can be applied in 40 responsible use of antibacterial in chronic wound management and as an illumination in 41 development of more potent antibiotics for chronic wound treatment 42

- 43
- 44
- 45

46 Keywords: Antibiofilm, antimicrobial resistance, human pathogens, susceptibility, virulence,

- 47
- 48
- 49

### 50 Introduction

The six pathogens represented in the acronym ESKAPE (Enterococcus faecium, Staphylococcus 51 aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 52 *Enterobacter* species) exhibit multidrug-resistance and virulence, and are attributed to a majority 53 54 of nosocomial infections [1,2]. These organisms mostly infect wounds as it offers a moist, warm, nutritive environment advantageous to microbial colonization, spread, and infection [3-6]. 55 56 Different bacterial species live on human skin, in the nasopharynx, gastrointestinal tract, and other parts of the body with little latent for causing disease, because of the skin being the first line of 57 defense within the body [7, 8]. Any breach in the skin surface whether through contact with 58 59 contaminated water, trauma, accident, surgical operation, or burn provides an open door for bacterial infections [7]. Consequently, wounds can be infected by a diverse array of 60 microorganisms ranging from bacteria to fungi and parasites as well as viruses [9,10]. 61

Unfortunately, the control of wound infections has become more challenging due to widespread 62 bacterial resistance to antibiotics, and to a greater incidence of infections caused by methicillin-63 resistance S. aureus, polymicrobial flora [11]. Although modernization of antimicrobials in the 64 20<sup>th</sup> and 21<sup>st</sup> century was meant to transform treatment of human infections; the fast-increasing 65 antimicrobial resistance poses a threat to mitigating infections. Antimicrobial resistance remains a 66 67 dynamic risk to the management of the rising range of infections caused by microorganisms [12], hence antibacterial drugs effectiveness is reduced making the management of patients demanding 68 and expensive inducing persistent sickness and increasing deaths on helpless patients [12]. 69 Progress of antimicrobial resistance is a normal incidence in microorganisms which is boosted due 70 71 to burden brought about by usage and mistreatment of antibiotics in organisms [13]. Lately, there has been a developing desire for identification antibiotics which are more powerful in resistant 72 bacteria management [13]. This is because the chief common bacteria have developed resistance 73 to common antimicrobials discovered recently [13, 14]. The absence of fresh antibiotics in the 74 World to substitute the incompetent one conveys more urgency to the desire to guard the 75 effectiveness of current medications, advancement and 76

enactment of suitable methods to curb the rise and spread of antimicrobial resistance [15].

78 In developing countries, antimicrobial resistance poses a great trial to community health care

79 motivating several researchers to determine the resistance profile of antibiotics against bacteria.

80 Nevertheless, the conclusions continue to produce different opinions on the drug's effectiveness.

For instance [16, 17] in Libya like [18] in Sudan revealed sensitivity to 54% amikacin and 59% ciprofloxacin but resistance to 81% vancomycin, 75% amoxicillin, 92% streptomycin, 45% tetracycline, 26% methicillin, 65% amoxicillin, and 46% erythromycin. On the other hand, it was displayed that bacteria were highly resistant to 96% ciprofloxacin in Nigeria [19], which opposes other findings.

The increasing problem of antimicrobial resistance remains a worrying nightmare across the world 86 prompting endless research and innovation approaches research on bacterial susceptibility and 87 resistance to antibiotics is a top interest sometimes presenting contradicting findings. For example, 88 in wound management, [19, 20] recognized that bacterial isolates were therapeutically responsive 89 to amoxicillin clavulanate, meropenem, clindamycin, ceftriaxone, piperacillin-tazobactam, 90 ciprofloxacin, vancomycin, levofloxacin, linezolid, teicoplanin, imipenem, meropenem, amikacin 91 and levofloxacin but resistant to ampicillin, Amoxicillin clavulanate, cotrimoxazole, doxycycline 92 and cephalosporins. Later studies [20] with similar focus presented e highly resistance to 93 cephalosporins, amoxicillin clavulanate and imipenem with disregard to [21] findings. 94

95

#### 96 Materials and Methods

97 An examining study was carried out in all the samples receive at the Medical Microbiology

98 Laboratory Department of Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH),

99 Kisumu county-Kenya for the period of March to June 2022. Samples (wound pus/swab) were

100 obtained from the patients who only attend JOOTRH both in Outpatient and Inpatient

101 department, patient referend to the hospital were not included in this study.

102 Following aseptic techniques, microscopy was performed to analyze for type and morphology of

bacteria. The samples were then inoculated on blood agar (BA), Mac-conkey agar (MA) and

104 chocolate agar (CA) following previously used and established standard protocols [22]. BA and

105 MA plates were incubated aerobically, while CA plates were incubated in anaerobic condition at

 $37^{0}$ C for 24 to 48 hours in the incubator. All the isolates were identified by colony morphology,

107 Gram staining reaction and the biochemical properties [22]. The antimicrobial susceptibility test

- 108 of isolates was performed by the Kirby-Bauer disc diffusion method using the CLSI guidelines
- 109 on Müeller-Hinton agar plates (Mast Diagnostics Ltd, Merseyside, UK) where 16 antimicrobials
- i.e. penicillin (25 μg), Ampicilin (10 μg), Vancomycin (15 μg), Cefoxitin (10 μg), Cefuroxime
- 111 (30 μg), Oxacillin (15 μg), Ciprofloxacin (10 μg), Clindamycin (25 μg), Co-trimoxazole (30

- μg), Tetracycline (15 μg), Erythromycin (10 μg), Gentamicin (30 μg), Ceftriaxone (10 μg),
- 113 cefepime  $(30 \mu g)$ , Imiperine  $(10 \mu g)$  and Amikacine  $(30 \mu g)$  will be used in this study.as
- outlined by Clinical and Laboratory Standards Institute (CLSI) (2022) [23]. After this isolated S.
- aureus was screened for methicillin resistance using cefoxitin disc (30 µg) as per standard
- 116 guidelines provided by CLSI, (2022). MICs of ciprofloxacin and gentamicin were determined by
- agar dilution method [25, 26] and the guidelines of the CLSI [23]. The tests were performed by
- making a series of antibiotic concentrations on Mueller–Hinton agar (MHA) plates. P.
- 119 *aeruginosa* spp. ATCC<sup>®</sup> 12934 and *S. aureus* ATCC<sup>®</sup> 29213 were used as reference strains
- 120 (controls). All the data were entered in SPSS version 20 and GraphPad Prism version 9.4.
- 121 Statistical analyses were done using the same software.

### 122 Biofilm formation inhibition assay

123 As described by Awuor et al. [27], microtiter plate assay was performed to quantify the effect of

124 commonly used antibiotics on the biofilm formation of *P. aeruginosa spp.* strains. The test

bacteria were first inoculated on Luria-Bertani (LB) medium agar and incubated at 37 °C

- 126 overnight. Then a colony was identified, picked and inoculated in 10 ml of LB broth and
- incubated at 37 °C overnight while shaking at 100 r.p.m. for 18 h. By use of a parafilm the flat-
- bottomed polystyrene tissue culture microplate was sealed for purposes of preventing medium

evaporation. After 48 h incubation, the wells were carefully rinsed with double-distilled water to

- remove loosely attached cells. The microplate was air-dried for 1 h before adding 200  $\mu$ L per
- 131 well of 0.4 % crystal violet (CV) solution to the adhered cells in the wells and then stood at room
- temperature for 15 min. Excess stain was removed by rinsing the wells gently with 200 μL per
- using distilled water. This was repeated thrice. The microtiter plate was then air-dried for 1 h
- after, followed by addition of 200 µL of absolute ethanol to each well to solubilize the dye. The
- 135 OD was measured at OD<sub>590nm</sub> using a Safire Tecan-F129013 Microplate Reader (Tecan,
- 136 Crailsheim, Germany). For each experiment, background staining was corrected by subtracting
- the crystal violet bound to un-treated controls (Blank) from those of the tested sample. The
- experiments were done in triplicate and average  $OD_{590nm}$  values were calculated. To estimate the
- antibiofilm activity (Abf A) of a given antibiotic the following equation was used,
- 140 Abf A (%) =  $(1-(OD_{Test sample} OD_{Blank})/(OD_{Untreated sample} OD_{Blank}) \times 100.$

#### 141 Monitoring presence of relevant virulence factors of *P. aeruginosa spp.*

### 142 (i) Detection of haemolysin

- 143 Haemolysin production by the *P. aeruginosa spp.* isolates were detected following protocols by
- 144 Benson et al. [28]. The β-haemolytic activity was tested for on base agar (Himedia, India)
- supplemented with 7 % sheep erythrocytes for 18–24 h. Pure isolates were cultured on TSA,
- before streaking on blood agar and further incubated for 24 h at 37 °C. Zones of haemolysis
- around the colonies indicated the ability of these bacteria to haemolyse RBCs [40].

# 148 *(ii) Detection of protease*

- 149 To detect protease production by the *P. aeruginosa spp.* isolate skim milk agar was used and the
- protocol that was described in [28]. Briefly, two solutions (A and B) were made and used in this
- 151 study. Solution A was prepared by adding 10 g skim milk to 90 ml of distilled water then volume
- use completed to 100 ml gently heated at 50 °C, then autoclaved and cooled to 50–55 °C. And
- solution B was also prepared by adding 2 g of agar powder to 100 mL of distilled water, mixed
- thoroughly, then autoclaved and cooled to 50–55 °C. Aseptically, 100 ml of solution A was
- mixed with 100 mL of solution B. Then the mixture was poured into sterile petri dishes, and then
- stored at 4 °C until use. This media used to detect the ability of the bacteria to produce protease
- 157 [46]. The appearance of a cleared hydrolysis zone indicates a positive test [29].

### 158 (iii) Detection of lipase

- 159 Lipase production ability by *P. aeruginosa spp.* isolates were determined by methods outlined by
- 160 Elliot et al. [29]. Briefly, a single colony of an overnight growth was cultured on Rhan medium,
- and then incubated for 1–5 days at 37 °C. The appearance of a turbid zone around colonies
- indicates a positive result [28].
- 163 *(iv) Detection of lecithinase (phospholipase)*
- 164 To detect lecithinase, we followed a standard procedure [30]. One pure colony was cultured on a
- 165 medium of phospholipase activity assay followed by incubation for 1–3 days at 37 °C using
- 166 established procedures [31]. The appearance of a white to brown colour elongated precipitated
- zone around colonies is considered a positive result [32].
- 168 Validity and reliability

All experiments were conducted in triplicates that were independent of each other to validatereproducibility.

171 Data analysis

Statistical analysis was performed using Graph pad Data on socio-demographics were summarized
by frequencies and percentages. All values of diameter zones of inhibition are reported as mean ±
standard error.

#### 175 Ethical consideration

Confidentiality and privacy were strictly adhered to and no names of individuals were recorded or made known in the reporting of information. The study was granted ethical clearance by the Institutional Research Ethics Committee (IREC) at Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), written informed consent was obtained from the parent/guardian of each participate in this study.

181

### 182 **Results.**

Of 135 samples processed, 73 (54.1%) showed their growth as shown in Supplementary data 1. 183 A-F. Among growth positive cases, 37(27.4%) were Gram positive while 36 (26.7%) were Gram 184 negative and 62 (45.9%) did not show growths. High rate of growth positive rate in infection was 185 found in case of male gender with Gram-positive cocci isolates at 23 (29.1%) and Gram-negative 186 cocci isolates at 26 (32.9%) than female gender with Gram-positive isolates of 14 (25.5%) and 187 Gram-negative isolates of 10 (18.2%), which were found to be statistically significant (p-value <188 0.075). Among total growth, the highest growth rate was found in age groups >45 years in both 189 Gram-positive and Gram-negative at 14 (26.9%) and 12 (23.1%) respectively. Least growth was 190 found in an age group of < 5 years and 25-34 years as shown in **Table 1**. 191

Out of the total wound swab samples analyzed 71 (52.6%) were from swab while 64 (47.4%) 192 193 were aspirate samples in which higher percentage growth was observed on aspirate than swab sample as in **Table 2**. Out of the 73(54.1%) growth positive wound swab samples, 37 (27.4%) 194 195 Gram- positive bacteria were found, while 36 (26.7%) Gram- negative bacteria were isolated. Among the Gram-positive isolates, S. aureus 28 (20.7%) was the most predominant followed by 196 Staphylococcus spp. 9 (6.7%) while in Gram-negative isolates the most predominant organism 197 was Klebsiella spp. 20 (14.8%) followed by P. aeruginosa spp. 10 (14.8%) and lastly E. coli at 6 198 199 (4.4%) as shown in **Table 2**.

Among 37 (27.4%) Gram-positive isolates, 28 (20.7%) S. aureus resistance pattern showed that 200 the most effective antibiotics were cotrimoxazole 13 (48.1%) followed by clindamycin 7 (25.9%) 201 202 and erythromycin 7 (25.9%) while lower resistant to cotrimoxazole 3 (37.5%) was observed on Staphylococcus spp. as compared to S. aureus. In 36 (26.7%) Gram-negative isolates, 20 (14.8%) 203 Klebsiella spp. resistance pattern showed that the most affected antibiotic was tetracycline 11 204 (61.1%) followed by gentamicin at 9(50%) while for P. aeruginosa four isolates show MRD to 205 commonly used antibiotics, while for E. coli it was found that the isolates were sensitive to 206 almost all of the common antibiotic used in the facility for their management as shown in **Table** 207 3 and Supplementary data 2. A-C. 208

Among the total 10 (7.4%) *P. aeruginosa* isolates, 4 isolates (12583;14421;1364 & 11985) were

found to have multi drug resistance. Among MDR isolates, 2 isolates (12583 & 13642) were

resistant to 3 antimicrobial classes, 1 isolate (13642) was resistant to four antimicrobial classes; 2

isolates (14421 & 13642 were resistant to five classes; 1 isolate (11985) was resistant to six

antimicrobial Classes as shown in Fig. 1.

This study investigated the production of various virulence enzymes like protease,

215 phospholipase, lipase and haemolysin on the four *P. aeruginosa* isolates which showed MRD

and were found to be resistant to common antibiotics used for its management within the study

area. It was revealed that out of the 10 isolates four isolates showed resistance at different

antimicrobial classes in which out of the four isolates, isolate **14421** was able to produce all

types of the virulence enzymes. Also, it was confirmed that isolate 12583 was able to produce all

enzymes except phospholipase enzyme while isolate **11985** was also capable of producing all

except lipase enzyme. Lastly, it was determined that isolate **13642** was not able to produce all the

virulence enzymes as shown in **Table 4**.

223 The isolates showed that the biofilm formation inhibitory effects of the various concentrations

224  $(0.5, 0.25, 0.125, 0.0625 \text{ and } 0.03125 \text{ mg ml}^{-1})$  were significantly lower than that of the

positive control, an indication that biofilm formation was inhibited at these concentrations (Figs.

226 2–4). As much as such inhibitory effects were recorded, these findings clearly demonstrate that

out of the four isolates that proved to be resistant to commonly used antibiotics, three isolates

228 (12583; Fig.2,14421; Fig. 3 and 11985; Fig. 4) have the ability of forming biofilms.

Antibiofilm formation activity against isolate 14421 of P. aeruginosa against various antibiotics 229 like Ciprofloxine, Cefuroxime, Ceftriaxone, Ampicillin, Gentamicin and Amikacin against 230 was observed in all the antibiotics (Fig. 4). Against ampicillin, a concentration of 0.0125 mg 231 ml<sup>-1</sup> and 0.0625 yielded significant biofilm formation inhibition (P=0.05), while for 232 233 Gentamicin obtained significant differences on the biofilm formation inhibition at a concentration of 0.5 mg ml<sup>-1</sup> (*P*=0.0001), 0.25 mg ml<sup>-1</sup> (*P*=0.0001), 0.125 mg ml<sup>-1</sup> 234 (P=0.0001). 0.0625 mg ml<sup>-1</sup> (P=0.0001) and 0.03125 mg ml<sup>-1</sup> (P=0.0001) was observed in 235 236 all the isolates. It is more worrying that Ciprofloxine, which is the commonly used antibiotic in

the hospital, had less inhibitory effects against biofilm formation most so in the isolate 12583.

#### 238 Discussion.

237

In this study, out of 135 samples from patients with wound infection, 73 (54.1%) samples 239 240 showed positive growth. In similar studies conducted earlier by [22] in antibiotic susceptibility pattern of bacterial isolates causing wound infection among the patients visiting B & B Hospital 241 242 in India, [25] showed growth positive was 44.9% & 50% respectively. A study conducted by [26,27] in the tertiary hospital in South Africa, more than 90% showed growth. Culture negative 243 results observed in this study could be attributed to the non-infective bacteria, manual error in 244 collection, transportation, overstaying of samples to reach Laboratory department culture media 245 and collection of samples from patients taking antibiotics. The growth was seen to be higher in 246 male patients in both Gram- positive and Gram- negative isolates at 23(29.1%) and 26(32.9%) 247 respectively. A Similar study carried out by [24] agrees with our findings. The relatively higher 248 percentage of male patients might be due to active involvement of males in outdoor activities, 249 including agricultural work resulting in high infection possibility and prevalence of high rate of 250 251 accidental cases among them [28].

From the total growth of 54.1%, the highest growth rate was found in age group >45 years

followed by 6-14, 15-24, 25-34, 35-44 and lastly <5 years, our findings disagree with the studies

carried out by [27,28] which showed highest growth rate in age group 21-30 (25.4%), followed

by 31-40 (16.2%) and 11-20 (16.2%). Least growth was found in an age group of 0-10 and above
60 years. The reason behind this age group (>45) showing high growth among all age classes
may be due to high prevalence of this age group in our study as well as the group being lively
age group or working age group hence the chances of occurring accidents leading to hospital
admission.

From the total bacterial isolates, 37(27.6%) were Gram positive and 36 (26.9%) were Gram 260 negative bacteria. This result didn't concur with a study conducted by [21-33] which shows 261 262 Gram negative bacteria being predominant since their peptidoglycan layer is much thinner than 263 that of Gram-positive bacilli and they are harder to kill because of their harder cell wall in which 264 when their cell wall is disturbed release endotoxins that can make your symptoms worse [25]. Our observation of Gram negative as the most common bacteria in wound infections differs from 265 266 other studies in Nigeria reporting Gram positive to be predominant [29]. Among the gramnegative isolated pathogens Klebsiella spp. was the most predominant 20(14.8%), The 267 pathogenicity of K. pneumoniae is mediated by several virulence factors that allow it to evade 268 host innate immune responses. These factors include the capsule, lipopolysaccharide, adhesins, 269 270 iron acquisition systems, resistance to serum, and biofilm formation [24]. While for the Grampositive S. aureus was the predominant isolate 28 (20.7%) and 1st predominant isolates among 271 the total. S. aureus pathogenicity is mediated by bacterial components and secreted virulence 272 factors such as surface-associated adhesins, capsular polysaccharide (CP), and exotoxins [29]. 273 274 This finding didn't concur in a similar study conducted by [32]. P. aeruginosa was the most 275 predominant one (29.9%) among the total isolates this may be due to the permeability barrier afforded by its Gram-negative outer membrane, while S. aureus was predominant (27.5%) 276 among Gram positive isolates. The study conducted by [32] Gram-negative bacilli constituted 277 66% of all the pathogens with *P. aeruginosa* as the most frequent (19%). Higher prevalence of *S.* 278 279 *aureus* among Gram-positive bacteria and 1<sup>st</sup> predominant isolates among the total seen in this 280 study was also reported by other researchers, [35, 36]. Many researchers said that it is most commonly isolated. S. aureus was ubiquitous and the most common cause of localized 281 282 suppurative lesions in human beings.

In the susceptibility patterns towards Gram-positive isolates, *S. aureus* isolates showed an
alarmingly resistance to cotrimoxazole (48.1%), a commonly used antimicrobial drug in wound

management Studies have shown S. aureus can become drug-resistant either via genetic 285 mutations on DNA gyrase or through reduced expression of outer membrane proteins reducing 286 287 drug accumulation [53]. Our findings corroborate previous studies [37] [38,39] that reported 47% and 49% resistance towards cotrimoxazole respectively. With cotrimoxazole has been the 288 first-line treatment for wound infections, and it is commonly prescribed not only for wound 289 infection but also for gastrointestinal tract infections, including diarrhea, but also for the 290 291 treatment of respiratory tract infections, urinary tract infections and skin infections. Its mode of 292 action is by targeting a subunit of DNA gyrase, which is essential in the production of bacteria DNA (39). It is often prescribed to immunocompromised patients, including human 293 294 immunodeficiency virus (HIV) patients, which are common in the study area with a prevalence of 16.3% [38]. Such a vast usage of cotrimoxazole, and the fact that it is relatively cheap and 295 296 could be acquired over the counter even without a prescription, may have contributed to the emergence of resistance towards this antibiotic as observed in this study. 297

A high incidence of Erythromycin resistant to S. aureus isolates (25.9%) was also observed. 298 Erythromycin is a bacteriostatic and broad-spectrum antibiotic effective against a wide variety of 299 Gram-positive bacteria. Its mode of action is by irreversibly binding to a receptor site on the 50S 300 301 subunit of bacterial ribosome, inhibiting peptidyl transferase, consequently resulting in the prevention of amino acid transfer to growing peptide chains, leading to inhibition of protein 302 synthesis. Up to late 2018, it was used as the first-line antibiotic treatment for typhoid and other 303 Salmonella infections [32]. However, because of resistance and safety issues, it is no longer the 304 first-line treatment in enteritis. In low-income countries, it is still widely used, as it is not 305 expensive and readily available [40]. Erythromycin has been recommended by the World Health 306 307 Organization (WHO) for the treatment of wound infection in both children and pregnant women [44]. The high resistance observed may be explained by its frequent usage for the treatment of 308 309 severe cough and other infectious diseases. Also, Erythromycin resistance was found to be due 310 predominantly to the presence of an Erm(B) methylase. Other reports have indicated that S. 311 aureus isolates are resistant to Erythromycin [37]. A similar incidence was observed for other pathogens causing diarrhea in a study conducted in the study area [42]. 312

A higher resistance rate of *Klebsiella spp.* to ampicillin (61.1%) was observed compared to that towards Gentamicin (50%), whose mode of activity is by targeting penicillin-binding proteins – a

group of enzymes found anchored in the cell membrane, involved in the cross-linking of 315 bacterial cell wall. *Klebsiella spp.* isolates from previous wound infections were known to 316 317 exhibit resistance to ampicillin, [43] Gentamicin and Imipenem [43]. There was an emergence of P. aeruginosa isolates resistant to ampicillin (33.3%), Gentamicin, Amikacin and Ceftriaxone all 318 at (20%), with 10 isolates resistant to this antimicrobial which has been primarily associated with 319 the presence of IncC conjugative plasmids [44], hence leading to 4 isolates being found to be 320 multi drug resistance. Among the MDR isolates, 2 showed resistance to 3 antimicrobial classes, 321 1 resistant to four antimicrobial classes; 2 resistant to five classes and finally 1 was resistant to 322 six antimicrobial Classes. Studies on MRSA have shown their wide variation. Naik and 323 Deshpande (2011) [45] showed 8.0% of MRSA which agree with our study. All E. coli isolates 324 were sensitive towards all the antibiotics used except lower resistance to Imipenem, thus 325 326 confirming the higher efficiency of these agents against *E. coli* isolates at Kisumu County.

Surprisingly, out of the four isolates, 3 (75%) isolates (12583, 14421 & 11985) were able to 327 produce the haemolysin, a finding that didn't conform with a previous study [46] which shows 328 100% isolates producing the enzyme. As stated before, purified haemolysin can cause fluid 329 330 accumulation [32], in contrast to the watery fluid produced in response to CT, the accumulated 331 fluid produced in response to haemolysin is invariably bloody with mucus [32]. Also, out of the four isolates 2 (50%) (12583 and 14421) had the ability to produce lipase. Our findings also 332 concur with other studies, which showed that 50% isolates obtained in the study had the ability 333 to produce lipase [16]. Lipase enzymes catalyze the hydrolysis of the ester bonds of 334 335 triacylglycerols and may have a critical role in P. aeruginosa pathogenicity or nutrition acquisition. The production of an excess lipase allows bacteria to penetrate fatty tissue with the 336 consequent formation of abscesses [48]. The production of these enzymes by the isolates may 337 reflect the presence of genetic organization of a discrete genetic element, which encodes three 338 genes responsible to produce proteases, lipases and phospholipase. This organization could be a 339 possible part of a pathogenic island, encoding a product capable of damaging host cells and 340 being involved in nutrient acquisition [49]. 341

Some studies have suggested that Cefuroxime and Amikacin do inhibit growth at high
concentrations [50, 51] but from this study, it was deduced that they inhibit biofilm formation at
both lower and higher concentrations. The same scenario was also observed in most antibiotics

345 like Ciprofloxine, Ampicillin, ceftriaxone and Gentamicin with such 'Goldilocks' effect. A 346 possible explanation to the less activity observed at greater doses could be associated with the 347 aggregation effects of the antibiotics at site of entry into bacteria cells especially at high dosages 348 something that is not observed at lower dosages. It is likely that aggregation may favor biofilm 349 formation as antibiotics struggle to reach the point of action and hence bacteria will continue to 350 thrive and hence form more biofilms [52].

#### 351 CONCLUSION

The world is in dire need of improved antimicrobial owing to escalating AMR by a wide array of 352 microbes on current antimicrobial pharmaceutics. This calls for a continuum of research efforts 353 and innovation strategies aimed to catch up with AMR pace. This includes gene-mining 354 355 applications, high-throughput genetic sequencing and molecular biology approaches, as well as, the recent incorporation of in silico tools and artificial intelligence (AI) in the antimicrobial 356 357 search. That said, the collection of clinical AMR data remains pivotal in monitoring trends in antimicrobial resistance, in development of improved AMR drugs and in incorporation of 358 359 innovative strategies such as AI. More focus is needed on the increasing bacterial antibiotic resistance especially in chronic wound management. 360

From this study, it can be concluded that antibiotic resistance patterns in Gram-positive and 361 Gram-negative bacteria are in an alarming trend that leads to the failure of treatment. The 362 resistance isolates do produce various virulence enzymatic factors such as haemolysin, lipase, 363 protease and phospholipase, that are pivotal to aiding bacterial resistance. As much as inhibitory 364 effects were recorded, these findings clearly demonstrate that the isolates proved to be resistant 365 to commonly used antibiotics and they do form biofilms. And from the higher positive growth on 366 367 the aspirant samples than the swab one we can conclude that the aspirant sample is the ideal sample for wound culture. 368

#### 369 Acknowledgements

We thank JOOTRH Laboratories-Kisumu, Kenya for providing laboratory space and other resources used this study lastly, we would like to thank all staff in the microbiology section for the analysis of the samples.

#### 373 Author contributions

All authors contributed equally to this work.

### 375 **Conflicts of interest**

The authors declare that there are no conflicts of interest.

### 377 **References**

1. Mulani, M.S., Kamble, E.E., Kumkar, S.N., Tawre, M.S. and Pardesi, K.R., 2019. 378 Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: 379 a review. Frontiers in microbiology, 10, p.539. 380 2. Rice, L.B., 2008. Federal funding for the study of antimicrobial resistance in nosocomial 381 pathogens: no ESKAPE. The Journal of infectious diseases, 197(8), pp.1079-1081. 382 383 3. Fauci, D. Longo, E. Braunwald et al., "Patient management algorithms," in *Harrison's* Principles of Internal Medicine, pp. 325–328, TheMcGraw-Hill Companies Inc, 17th 384 edition, 2008. 385 4. A. Shittu, D. Kolawole, and E. Ovedepo, "A study of wound infections in two health 386 institutions in Ile-Ife, Nigeria," African Journal of Biomedical Research, vol. 5, pp. 97-387 102, 2002. 388 5. P. G. Bowler, B. I. Duerden, and D. G. Armstrong, "Wound microbiology and associated 389 approaches to wound management," ClinicalMicrobiology Reviews, vol. 14, no. 2, pp. 390 244-269, 2001. 391 392 6. R. Cooper, "Understanding wound infection," in EWMA Position Docment: Identifying Criteria for Wound Infection, MEP Ltd, London, UK, 2005. 393 7. C. N. Ohalete, R. K. Obi, and M. C. EmeaKoroha, "Bacteriology of different wound 394 infection and their antimicrobial susceptibility patterns in Imo state Nigeria," World 395 Journal of Pharmaceutical Sciences, vol. 13, no. 3, pp. 1155–1172, 2012. 396 397 8. Church, D., S. Elsayed, O. Reid, B. Winston and R. Lindsay. 2006. Burn wound infection. Clin. Microbiol. Rev. 19: 403-434. 398 9. Gupta, N., V. Gautam, S. Saini, L. Singh, and D.R. Arora. 2002. Prevalence of multi drug 399 organism in wound infection. J. infect. Dis. Antimicrobial. Agent. 19: 111-117. 400 10. Esebelahie, N.O., F.O. Esebelahie and R. Omoregie. 2013. Aerobic bacterial isolates 401 from wound infection. Afr. J. Cln. Exper. Microbiol. 14: 155-159. 402 403 11. Shittu, A.O., D.O. Kolawole, and E.A.R. Oyedepo. 2002. Wonud infections in two health institutions in Ile Ife, Nigeria: A cohort Study. Afr. J. Biomed. Res 5:97-102. 404 405 12. Murugan S, Mani KR, Uma DP. Prevalence of methicillin resistant staphylococcus aureus among diabetes patients with foot ulcers and their antimicrobial susceptibility 406 pattern. Journal of Clinical and Diagnostic Research. 2008; 14(2): 979-984. 407 13. Jain SK, Barman R. Bacteriological profile of diabetic foot ulcer with special reference to 408 drug-resistant strains in a tertiary care center in North-East India. Indian Journal of 409 Endocrinology and Metabolism. 2017; 21(5): 688-694. 410 411 14. Alsadig MA, Elzen AA, Alshahed A, Gurfa AA, Aziza HM, Gaeidaa AM, et al. Identification and determination of antibiotic resistance of pathogenic bacteria isolated 412 from septic wounds. Journal of Advanced Laboratory Research in Biology. 2015; 6(5): 413 97-101. 414

| 415        | 15. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to  |
|------------|--|
| 416        | combat ESKAPE pathogens in the era of antimicrobial resistance: A review. Frontiers in                                       |
| 417        | Microbiology. 2019; 10: 539-544.   |
| 418        | 16. Moellering RC. Linezolid: The first oxazolidinon antimicrobial. Annals of Internal                                       |
| 419        | <i>Medicine</i> . 2003; 138(2): 135-42.  |
| 420        | 17. Ibrahim, A. A., Bhatawadekar, M. S., Peerzada, B. Y., Modak, M. M., & Lahiri, K. K.                                      |
| 421        | (2016). Bacterial profile of diabetic foot ulcer- Study from Western India. International                                    |
| 422        | Journal of Health Sciences and Research. (2016); 6 (5), 65-71.   |
| 423        | 18. Pai, D. R., & Madan, S. S. Techniques in chronic wound management: Review of the   |
| 424        | literature and recent concepts. Journal of Novel Physiotherapies. (2013); 3 (2), 1-7.  |
| 425        | 19. Pokhrel P, Shrestha A, Panthi P, Manadhar S, Chaudhary DK. Bacteriological profile and                                   |
| 426        | antibiotic susceptibility pattern of wound infection in children. <i>Ecronicon Microbiology</i> .                            |
| 427        | 2017; 5(3): 93-100.  |
| 428        | 20. Gupta, V. An update on newer $\beta$ -lactamases. <i>Indian Journal of Medical Research</i> .                            |
| 429        | (2007); <i>126</i> , 417-427.  |
| 430        | 21. Hout, B., Oum, C., Men, P., Vanny, V., Supaprom, C., Heang, V., et al. Drug resistance                                   |
| 431        | in bacteria isolated from patients presenting with wounds at a nonprofit surgical center in                                  |
| 431        | Phnom Penh, Cambodia from 2011–2013. <i>Tropical Diseases, Travel Medicine and</i>   |
| 432        | Vaccines. (2015); 1 (4), 1-11.   |
| 433        | 22. Cheesbrough M (2006). <i>District Laboratory Practice in Tropical Countries</i> . 2 <sup>nd</sup> edn.                   |
| 434        | Cambridge. Newyork, Melbourne, Madrid, Cape Town, Singapore, Sao Poulo:  |
|            | 0 1 1 1 01   |
| 436<br>437 | Cambridge University Press.<br>23. CLSI. 2022. Performance standards for antimicrobial susceptibility testing. thirty-second |
|            |  |
| 438        | Informational Supplement.33:1-199.   |
| 439        | 24. Magiorakos, A.P., Srinivasan A., Carey, R.B., Carmeli Y., Falagas, M.E., Giske C.G.,                                     |
| 440        | Harbarth S., Hindler, J.F., G. Kahlmeter, Olsson-Liljequist B., Paterson D.L., Rice L.B.,                                    |
| 441        | Steling J., Struelens, M.J., Vatopoulos, A., Weber, J.T. and Monner, D.L. 2012.  |
| 442        | Multidrugresistant, extensively drug resistant and pandrugresistant bacteria: an   |
| 443        | international expert proposal for interim standard defination for acquired resistance. Clin.                                 |
| 444        | Microbiol. Infect. 18: 268-281.  |
| 445        | 25. European Committee for Antimicrobial Susceptibility Testing: 2000. Determination of                                      |
| 446        | minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution.   |
| 447        | Eucast Definitive Document. E. Def 3.1.  |
| 448        | 26. Andrews, J.M 2001. Determination of minimum inhibitory concentrations. Journal of  |
| 449        | Antimicrobial Chemotherapy Suppl. 48, SL, 5-16.  |
| 450        | 27. Awuor, S.O., Omwenga, E.O., Mariita, R.M. and Daud, I.I., 2022. Cholera outbreak:  |
| 451        | antibiofilm activity, profiling of antibiotic-resistant genes and virulence factors of                                       |
| 452        | toxigenic Vibrio cholerae isolates reveals concerning traits. Access Microbiology, 4(3).                                     |
| 453        | 28. Benson HJ. Microbiological Applications: Laboratory Manual in General Microbiology.                                      |
| 454        | 8th edn. Complete version. U.S.A: McGraw-Hill; 2002.   |
| 455        | 29. Elliot EL, Kaysner CA, Jackson L, Tamplin ML. Valnificus and other Vibrio spp. In:                                       |
| 456        | Merker R (eds). Food and Drug Administration: Bacteriological Analytical Manual,   |
| 457        | Chapter 9, 8th ed. Gaithersburg, MD: AOAC International; 2001  |
| 458        | 30. Dogan B, Boor KJ. Genetic diversity and spoilage potentials among Pseudomonas spp.                                       |
| 459        | isolated from fluid milk products and dairy processing plants. Appl Environ Microbiol  |
| 460        | 2003; 69:130–138.  |

| 461 | 31. | . CLSI. Performance standards for antimicrobial sensitivity testing. 30th ed. CLSI          |
|-----|-----|---|
| 462 |     | supplement M100. Wayne, PA: Clinical Laboratory Standards Institute. 2010.                  |
| 463 | 32. | . Halpern M, Izhaki I. Fish as hosts of Vibrio cholerae. Front Microbiol 2017; 8:282.       |
| 464 | 33. | . Akinjogunla, O. J., Adeko, A.A., Mboto, C.I., Chukwudebelu I.C. and Udokang I.p.          |
| 465 |     | 2009. Bacteriology of framycetin and silver sulphadiazine as topical agents for burn. A     |
| 466 |     | pilot study. Burns. 35: 672-676.  |
| 467 | 34. | . Giocometti, A., O. Cirioni, A.M. Schimizzi, M.S. Del, F. Prete, M.M.D Barchiesi, E.       |
| 468 |     | Errico, G. Petrelli and J. ScaliSe. 2000. Epidemiology and microbiology for surgical        |
| 469 |     | wound infection. J. Clin. Microbiol. 38: 918-922.   |
| 470 | 35. | . Iregbu, K.C., N.S. Uwaezuoke, I.P. Nwajiobi-Princewill, S.O, Eze, N. Medugu , S.          |
| 471 |     | Shettima and Z, Modibbo. 2013. A profile of wound infecgtion in national hospital           |
| 472 |     | Abuja. Afr. J. Cln. Exper. Microbio. 14: 160-163.   |
| 473 | 36. | . Esebelahie, N.O., F.O. Esebelahie and R. Omoregie. 2013. Aerobic bacterial isolates       |
| 474 |     | from wound infection. Afr. J. Cln. Exper. Microbiol. 14: 155-159.                           |
| 475 | 37. | . Thanni, L.O.A., O.A. Olubunmi, and M.D. Agboola. 2003. Prevalence of bacterial            |
| 476 |     | pathogens in infected wound in a tertiary hospital, (1995-2001): J. Natl. Med. Assoc.       |
| 477 |     | <b>95</b> :1189-1195.   |
| 478 | 38. | Mehta, P.A., C.K. Cunningham, L.B. Colella, G. Alferis and L.B. Weiner. 2000. Risk          |
| 479 |     | factors for sternal wound infection and other infection in pediatric cardiac surgery        |
| 480 |     | patients. J. Pediatr. Infect. Dis. 19: 1000-1004.   |
| 481 | 39. | Mohammed, A., G.O. Adeshina, and Y.K.E. Ibrahim. 2013. Retrospective incidence of           |
| 482 |     | wound infections .and antibiotic sensitivity pattern: A study conducted at the Aminu        |
| 483 |     | Kano Teaching Hospital, Kano, Nigeria. International Journal of Medicine and Medical        |
| 484 |     | <i>Sciences</i> <b>5</b> : 60-66.   |
| 485 | 40. | Jawetz E, Melnick JI, Adelberg EA. Medical Microbiology. 27th Edn. Appleton and             |
| 486 |     | Lange U.S.A, 2016.  |
| 487 | 41. | . Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, et al. Toxin, toxin-         |
| 488 |     | coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in    |
| 489 |     | humans. J Exp Med 1988; 168:1487–1492.  |
| 490 | 42. | . Chen L, Wen Y. The role of bacterial biofilm in persistent infections and control         |
| 491 |     | strategies. Int J Oral Sci 2011; 3:66-73.   |
| 492 | 43. | . Jabik NA. Study of some Genetic Aspects of Isolated V. cholerae in Babylon. M.Sc.         |
| 493 |     | Thesis, University of Babylon, Iraq; 2000.  |
| 494 | 44. | Poole K. Bacterial stress responses as determinants of antimicrobial resistance. J          |
| 495 |     | Antimicrob Chemother 2012; 67:2069–2089.  |
| 496 | 45. | Ammons MCB. Anti-biofilm strategies and the need for innovations in wound care.             |
| 497 |     | Recent Pat Antiinfect Drug Discov 2010; 5:10–17.  |
| 498 | 46. | . Tan S-E, Chew SC, Tan S-Y, Givskov M, Yang L. Emerging frontiers in detection and         |
| 499 |     | control of bacterial biofilms. Curr Opin Biotechnol 2014; 26:1-6.                           |
| 500 | 47. | . Naik, G. and S.R. Deshpande. 2011. A study on surgical site infections caused by          |
| 501 |     | Staphylococcus aureus with a special search for methicillin-resistant isolate. J. Clin. and |
| 502 |     | <i>Diag. Research.</i> 5:502-508.   |
| 503 | 48. | Abbass NBM. Effectiveness of some physical and chemical factors on the morphological        |
| 504 |     | changes of Vibrio cholerae isolated from environment. Ph.D. Thesis, University of Al        |
| 505 |     | Mustansyria, Iraq; 2006.  |

- 49. Al-Hadrawy HAN. *A Comparative study of Bacteriological and Molecular Vibrio Cholera Isolated from the Tigris and Euphrates.* PhD Thesis, University of Kufa in
  Arabic, Iran; 2012.
  50. Ammons MCB. Anti-biofilm strategies and the need for innovations in wound care. *Recent Pat Antiinfect Drug Discov* 2010; 5:10–17.
- 51. Xu KD, McFeters GA, Stewart PS. Biofilm resistance to antimicrobial agents.
   *Microbiology* 2000; 146:547–549.
- 513 52. Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng,
  514 C. and Zhang, Z., 2020. Clinical and biochemical indexes from 2019-nCoV infected
- 514 C. and Zhang, Z., 2020. Clinical and biochemical indexes from 2019-nCoV infected 515 patients linked to viral loads and lung injury. *Science China Life Sciences*, *63*(3), pp.364-
- 516

374.

# 518 **Results.**

# **Table 1:** Sociodemographic characteristics of patients involved in the study for the period of

520 May to August 2022

| Characteristic   | Total (N, %)   | Gram Positive (n, %) | Gram Negative (n, %) | No Growth            | P Value |
|------------------|----------------|----------------------|----------------------|----------------------|---------|
| Age Category     |                |                      |                      |                      |         |
| < 5 years        | 12 (9%)        | 1 (8.3%)             | 6 (50%)              | 5 (41.7%)            | 0.199   |
| 6-14 years       | 24 (17.9%)     | 9 (37.5%)            | 6 (25%)              | 9 (37.5%)            |         |
| 15-24 years      | 15 (11.2%)     | 8 (53.3%)            | 2 (13.3%)            | 5 (33.3%)            |         |
| 25-34 years      | 16 (11.9%)     | 2 (12.5%)            | 6 (37.5%)            | 8 (50%)              |         |
| 35-44 years      | 15 (11.2%)     | 3 (20%)              | 4 (26.7%)            | 8 (53.3%)            |         |
| >45 years        | 52 (38.8%)     | 14(26.9%)            | 12 (23.1%)           | 26 (50%)             |         |
| Median Age (IQR) | 34 (IQR 13-56) | 25 (IQR 12-54)       | 32.5 (IQR 12-53.5%)  | 43 (IQR 22-<br>59.5) |         |
| Gender           |                |                      |                      |                      |         |
| Female           | 55 (41%)       | 14 (25.5%)           | 10 (18.2%)           | 31 (56.4%)           | 0.075   |
| Male             | 79 (59%)       | 23 (29.1%)           | 26 (32.9%)           | 30 (38%)             |         |
| Total            | 134            | 37 (27.6%)           | 36 (26.9%)           | 61 (45.5%)           |         |

| Sample   | e Total | (N, %) S. A | Staph<br>ureus spp. |      |           | P.<br>Aeruginosa | <b>E. coli</b> | No growth  |
|----------|---------|-------------|---------------------|------|-----------|------------------|----------------|------------|
| Swab     | 71(52   | 2.6%) 9(12  | 7%) 3(4.2%          | %) 3 | 8(4.2%)   | 1(1.4%)          | 0%             | 55 (77.5%) |
| Aspirate | e 64(47 | 19(2        | 9.7%) 6(9.4%        | %) 1 | 7(26.6%)  | 9(14.1%)         | 6(9.4%)        | 7 (10.9%)  |
| Total    | 135(1   | .00%) 28(2  | 0.7%) 9(6.79        | %) 2 | 20(14.8%) | 10(7.4%)         | 6(4.4%)        | 62 (45.9%) |

# **Table 2:** Distribution of pathogens by sample type and gram staining technique.

## **Table 3:** Antibiotic resistant patterns of isolated pathogens

| Gram Positive          | Cefoxitin         | Oxacillin         | Vancomy<br>cin | Penicillin      | Cotrimoxa<br>zole | Clindamy<br>cin | Tetracycl<br>ine | Gentami<br>cin | Erythromycin |
|------------------------|-------------------|-------------------|----------------|-----------------|-------------------|-----------------|------------------|----------------|--------------|
| S. aureus              | 3(11.1%)          | 2(7.4%)           | 2(7.4%)        | 5(18.5%)        | 13(48.1%)         | 7(25.9%)        | 5(18.5%)         | 4(14.8%)       | 7(25.9%)     |
| Staphylococcus<br>spp. | 2(25%)            | 0%                | 1(12.5%)       | 1(12.5%)        | 3(37.5%)          | 1(12.5%)        | 1(12.5%)         | 1(12.5%)       | 1(12.5%)     |
| Gram Negative          | Cotrimoxaz<br>ole | Ciprofloxa<br>cin | Cefuroxi<br>me | Ceftriax<br>one | Cefepime          | Imipenem        | Ampicilli<br>n   | Gentami<br>cin | Amikacin     |
| Klebsiella spp.        | 5 (27.8%)         | 4 (22.2%)         | 1 (5.6%)       | 3 (16.7%)       | 3 (16.7%)         | 6 (33.3%)       | 11(61.1%)        | 9 (50%)        | 2 (11.1%)    |
| P. aeruginosa          | 0%                | 1(10%)            | 2 (20%)        | 1 (10%)         | 1(10%)            | 3 (33.3%)       | 2 (20%)          | 2 (20%)        |              |
| E. coli                | 0%                | 0%                | 0%             | 0%              | 0%                | 1(16.7%)        | 0%               | 0%             | 0%           |

525


# **Table 4:** Detection of some virulence factors of *P. aeruginosa*

528

| Isolates | Haemolysin | Protease | Lipase | Phospholipase |
|----------|------------|----------|--------|---------------|
| 12583    | +p         | +p       | +p     | -n            |
| 13642    | -n         | -n       | -n     | -n            |
| 14421    | +p         | +p       | +p     | +p            |
| 11985    | +p         | +p       | -n     | +p            |

529 p = Positive and n = Negative


**Fig. 1:** Multidrug resistance antimicrobial class resistant to P. *aeruginosa*.



531

**Fig. 2**. Antibiofilm formation activity against isolate **12583** of *P. aeruginosa* against various

- antibiotics: (a) Ciprofloxacin (b) Cefuroxime, (c) Ceftriaxone, (d) Ampicillin, (e) Gentamicin
- and (f) Amikacin; PC=P. aeruginosa ATCC<sup>®</sup> 12934 Positive control (n=3, ANOVA Dunnett's
- 536 multiple comparisons test; \*P=0.05; \*\*P=0.01; \*\*\*P=0.001; \*\*\*P=0.001).



537


538

Fig. 3. Antibiofilm formation activity against isolate 14421 of *P. aeruginosa* against various
antibiotics: (a) Ciprofloxacin (b) Cefuroxime, (c) Ceftriaxone, (d) Ampicillin, (e) Gentamicin

and (f) Amikacin; PC=*P. aeruginosa* ATCC<sup>®</sup> 12934 – Positive control (*n*=3, ANOVA Dunnett's

542 multiple comparisons test; \*P=0.05; \*\*P=0.01; \*\*\*P=0.001; \*\*\*P=0.001).





544

545

546

547 Fig. 4. Antibiofilm formation activity against isolate **11985** of *P. aeruginosa* against various

- antibiotics: (A) Ciprofloxacin (B) Cefuroxime, (C) Ceftriaxone, (D) Ampicillin, (E) Gentamicin
- and (F) Amikacin; PC=P. aeruginosa ATCC® 12934 Positive control (n=3, ANOVA Dunnett's
- 550 multiple comparisons test; \*P=0.05; \*\*P=0.01; \*\*\*P=0.001; \*\*\*P=0.001).

552

